Quick Facts

• Acute Pain Management: Indicated for managing moderate to severe short-term pain in adult patients.
• Post-Surgical Discomfort: Used to help control pain following surgical procedures.
• Alternative Option: Provides a non-opioid treatment option for managing pain.

---

Supracalm is a prescription medication utilized in the management of pain. It is indicated for use in adult patients experiencing moderate to severe acute pain. Acute pain is defined as short-term pain, often occurring in response to tissue injury, such as from trauma or following a surgical procedure.

The medication's primary therapeutic domain is to help alleviate discomfort. Supracalm is often employed in the hospital setting or for a limited period following discharge to support patient comfort and pain control. It offers a non-opioid alternative for pain relief, which is part of the effort to broaden options for pain management.

This medication serves as a therapeutic option for acute pain and provides a choice within the class of non-opioid pain-management medicines.

The eligibility to use Supracalm (Acetaminophen/Paracetamol) is strictly defined by regulatory documents, focusing on patient status and underlying health conditions. Supracalm is contraindicated and must not be used by individuals with a known hypersensitivity to the drug or any component of the formulation. The medicine is also absolutely prohibited for patients diagnosed with severe hepatic impairment or active liver disease.

Use of Supracalm is restricted or requires conditional approval in several populations. Patients with severe renal impairment (creatinine clearance 30 mL/min or less) and those with risk factors like chronic alcoholism or glutathione-depleted states (e.g., chronic malnutrition) must use the medicine only under strict guidance.

Age-group eligibility permits use in adults, adolescents, and older adults. For pediatric populations, effectiveness for some acute pain applications is officially not established in children younger than two years. During pregnancy and lactation, use is permitted but is officially restricted to the lowest effective dose for the shortest duration necessary, as documented in regulatory guidelines.

Interactions with other medicines and products — official regulatory information for Supracalm

Interaction Scope

Category	Description based on Official Regulatory Documentation
Medicinal product categories with documented interactions	Hepatotoxic agents, Coumarin/Vitamin K Antagonists, Hepatic Enzyme Inducers, and Gastric Motility Modifiers.
Specific interacting medicines (if explicitly listed)	Warfarin, Probenecid, Phenytoin, Carbamazepine, Rifampicin, Cholestyramine, Metoclopramide, Isoniazid.
Mechanistic basis of interactions (only if stated in label)	Inhibition of clearance (Probenecid); CYP Enzyme Induction (Phenytoin); Altered absorption rate (Metoclopramide, Cholestyramine); Pharmacodynamic enhancement of anticoagulant effect (Warfarin).
Timing-based interaction rules (if applicable)	Co-administration with Cholestyramine requires time separation, typically with Supracalm administered at least one hour before or four hours after.
Population-specific interaction notes (if applicable)	The risk of liver damage is officially heightened in patients with severe hepatic impairment or chronic alcohol abuse when co-administered with inducing agents.
Interaction-related restrictions	The co-administration of Supracalm with any other product containing Acetaminophen is strictly prohibited.

Interaction classifications (high-level)

Classification Type	Description based on Official Regulatory Documentation
Interaction severity classification (as defined in official documents)	Includes Prohibited Combinations (additive exposure risk) and Clinically Significant Interactions requiring monitoring (anticoagulants, enzyme inducers).
Regulatory basis (EMA / FDA / etc.)	Interaction data is defined in the Summary of Product Characteristics (SmPC) and Prescribing Information across multiple national regulatory authorities.

Resulting interaction structure

Official interaction statements:

• Co-administration with any other Acetaminophen-containing product is strictly prohibited.
• The effect of Warfarin is officially enhanced with prolonged, regular co-administration of Acetaminophen, increasing the risk of bleeding.
• Enzyme-inducing medicines, such as Phenytoin and Rifampicin, are documented to increase the potential for forming the toxic metabolite of Acetaminophen.
• Substances like Probenecid inhibit the clearance of Acetaminophen, increasing systemic exposure and potential toxicity.
• The speed of absorption is officially increased by Metoclopramide and decreased by Cholestyramine.

Connection to the overall interaction profile (2–4 sentences): The regulatory profile is structured around prohibiting combinations that create additive hepatotoxic risk, particularly with other Acetaminophen products and chronic alcohol consumption. Key statements detail pharmacokinetic interference, such as the reduced clearance caused by Probenecid, and pharmacodynamic effects, specifically the potentiation of anticoagulants like Warfarin, as defined by official labeling restrictions.

How Supracalm Works

Supracalm operates as a calcineurin inhibitor, selectively targeting the protein phosphatase calcineurin. Following its intracellular entry, Supracalm binds to the immunophilin FK-binding protein 12 (FKBP12) to form a high-affinity complex. This resulting complex then interacts with and inhibits the activity of calcineurin.

Inhibition of calcineurin prevents its dephosphorylation of the nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) transcription factor. The consequent lack of NFATc1 nuclear translocation and gene activation leads to a decreased rate of differentiation and maturation of osteoclasts from precursor cells. This molecular cascade modulates bone physiology by contributing to the maintenance of balance between bone formation and resorption. Additionally, the mechanism regulates the transcription of specific cytokine production pathways, influencing aspects of the immune response.

Supracalm is a prescription medicine administered for the short-term management of acute pain within a supervised healthcare setting. The usage protocol mandates its administration solely via Intravenous (IV) Infusion.

Administration and Dosing

Standard dosing for adult patients weighing 50 kg or more is 1,000 mg per dose, while smaller patients receive a weight-based dose of 15 mg/kg. The frequency is governed by fixed intervals; the 1,000 mg dose is typically administered every six hours, but the minimum interval between any two doses, regardless of strength, must be no less than four hours. The Maximum Total Daily Dose from all sources—including IV, oral, and rectal intake—is strictly limited to 4,000 mg (4 grams) over a 24-hour period.

The IV solution must be infused slowly and consistently over a duration of 15 minutes. For smaller, weight-based doses, the appropriate volume must be accurately transferred to a separate container to ensure precise delivery. Prior to use, the container must be visually inspected for any discoloration or particulate matter, and the single-use vial mandates that any unused portion is discarded.

Population-Specific Scheduling

The dosing schedule applies to patients with severe renal impairment (Creatinine Clearance le 30 mL/min). In this specific population, the minimum interval between administrations is extended to six hours to ensure proper drug clearance. This adjustment is a key part of the standardized protocol.

Research evidence / Overview of Studies for Supracalm (Acetaminophen)

---

Evidence for Use in Mild to Moderate Pain Management

Research for this use has focused on short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies primarily examined outcomes related to physical discomfort, monitoring changes in pain intensity scores and the time until patients requested rescue medication. Studies reported measurements of how pain levels evolved over short periods, typically 4 to 6 hours. However, the evidence base is primarily relevant in trials assessing short-term or episodic symptom patterns, and long-term effects are not fully established through these trials.

---

Evidence for Use in Acute Post-Surgical Pain

Research has also evaluated Supracalm for moderate to severe pain after surgery, primarily through short-term RCTs. The studies monitored two main outcomes related to physical discomfort: changes in postoperative pain intensity scores and the total amount of opioid consumption requested for supplementary pain control. Studies explored whether patterns related to a measured change in pain scores were observed compared to placebo. Follow-up durations were limited to the immediate period (often 24 hours), and research provides limited insight into long-term functional recovery.

---

Evidence for Use in Fever Reduction (Antipyresis)

Research has explored the evidence base for fever reduction (antipyresis) in numerous RCTs and large Meta-analyses. This research was studied for outcomes related to systemic imbalance, measuring body temperature reduction and the duration of the effect. Findings were mixed when assessing differences between agents, but research describes patterns where a change in body temperature was noted. The studies mainly focused on the physical measure of temperature, and patient-reported outcomes describing perceived discomfort are less consistently studied.

---

Evidence in Specific Populations and Research Gaps

Research has been studied for children for pain and fever, where numerous RCTs exist. However, research focusing specifically on older adults with multiple health issues research describes that evidence is limited to fully characterize potential differences in effect compared to younger, healthier individuals. Overall, the majority of research is relevant in trials assessing short-term or episodic symptom patterns. A key area of uncertainty relates to conditions characterized by chronic, non-episodic pain, where the evidence base for this medicine is limited regarding its long-term management. Subgroup findings are uncertain when comparing options for highly complex patients, and results apply only to the populations studied.

Key Studies & References

1. NICE Guideline NG19: Fever in under 5s: assessment and initial management

Common questions about Supracalm (FAQ)

---

Q: Is Supracalm considered a controlled substance?

According to US drug schedules and official regulatory documents, the single active ingredient in Supracalm is not classified as a controlled substance. This means it is not typically regulated in the same way as medications with a high potential for abuse or dependence.

---

Q: How long does it typically take for Supracalm to start working?

Official product information indicates that the onset of action, which is when relief typically begins, usually occurs within 15 to 30 minutes following an oral dose. This is a general expectation based on clinical studies of the medicine.

---

Q: Does Supracalm make people feel 'drugged' or extremely sleepy?

Official safety documents for the single active ingredient generally do not list general drowsiness or extreme sleepiness as a frequently reported side effect. Side effects on the nervous system that are reported include headache and insomnia, but the safety profile does not commonly list sedation as a side effect.

---

Q: What is the risk of dependence or addiction with Supracalm?

Official regulatory documents and clinical information state that the single active ingredient in Supracalm does not become habit-forming. Therefore, the risk of physical or mental dependence is not noted in the official profile for this medication.

---

Q: Is Supracalm safe for older adults or seniors?

Regulatory guidance permits use in older adults, but the official protocol notes a requirement for caution regarding dose and duration. This adjustment is recommended due to the potential for increased sensitivity to the medicine or reduced organ function associated with advanced age.

---

Q: Can Supracalm affect my ability to drive or operate machinery?

Regulatory warnings commonly advise caution when performing skilled tasks if any medication causes effects like dizziness or lightheadedness. Official documents state that if such effects occur, engaging in skilled tasks may be impacted.

---

Q: How long does the effect of one dose of Supracalm last?

The pain-relieving and fever-reducing effect of a single dose is generally described in product information as lasting for 4 to 6 hours. This duration reflects the typical period before the body begins to process and clear the medication significantly.

---

Q: What is the purpose of the different strengths of Supracalm tablets?

Different available strengths, according to official labeling, are primarily intended to allow for flexibility in dosing. This includes facilitating precise, weight-based dosing for children and providing options for administering the required milligram amount to adults.

---

Q: Can Supracalm be taken on an empty stomach?

Regulatory information on pharmacokinetics notes that while the medicine can be taken without food, its absorption may be slightly delayed when taken with a meal. This is a common pattern for many oral medicines.

---

Q: Is there a maximum recommended period for using Supracalm?

The official over-the-counter labeling includes time limits, indicating that the medicine is generally not intended for use beyond 10 days for pain or 3 days for fever without specific guidance.

---

Q: Is Supracalm used to treat conditions other than its main approved use?

Official regulatory documents list the approved uses as the temporary relief of mild to moderate pain and fever reduction. Any other use of the medicine is not listed as an official approved indication by regulatory authorities.

---

Q: What should be done in the event of an overdose (general advice)?

Official guidance emphasizes that in case of suspected overdose, seeking immediate medical help is critical. Contacting emergency services or a Poison Control Center right away is essential, even if the individual does not feel symptoms.

---

Q: Does Supracalm interact with common cold or flu medicines?

Regulatory warnings strictly prohibit co-administration with any other product containing the active ingredient in Supracalm. Because of this prohibition, the need to confirm the ingredients of all co-administered products is stated in regulatory documents.

---

Q: Where can I find the official patient information leaflet for Supracalm?

Official patient information leaflets or equivalent public documents are typically made available on the websites of national regulatory agencies. Examples include the FDA's DailyMed or the European Medicines Agency's (SmPC) website.

---

Q: Why is monitoring sometimes required when taking Supracalm?

Monitoring may be required, according to regulatory warnings, due to specific risk factors. This is most relevant when co-administered with certain anticoagulant medicines or for patients with pre-existing liver or kidney conditions to mitigate defined risks.

---

Q: Is it okay to crush or chew Supracalm tablets?

Official labeling for immediate-release tablets may permit this practice, but regulatory documents require that extended-release or other modified formulations are swallowed whole. Crushing modified formulations can lead to the rapid release of too much medicine, potentially causing an overdose.

---

Q: What is the half-life of Supracalm?

The elimination half-life is defined in official pharmacokinetic studies, which describe how long it takes for half the medicine to be cleared from the body. This is generally reported as approximately 2 to 3 hours in healthy adults.

---

Q: Is the effect of Supracalm affected by age or gender?

Official documents note that the rate at which the body clears the medicine may be prolonged in patients with advanced age due to reduced organ function. However, the regulatory data does not commonly define differences in effect based on gender alone.

How to Store and Dispose of Supracalm?

Strict adherence to regulatory storage and disposal instructions ensures the stability and safe handling of Supracalm (Acetaminophen).

Storage Conditions

Supracalm must be stored at room temperature, typically below 25°C or 30°C. It is mandatory to keep the medicine in its original container and protect it from both moisture and light. A critical safety requirement is to store the product out of the sight and reach of children. Do not freeze the product.

Disposal Instructions

Unused or expired Supracalm must be disposed of according to local regulations for pharmaceutical waste. Do not dispose of the medicine by flushing it down the toilet or pouring it down a drain unless explicitly instructed by a national health authority. Prior to discarding packaging, ensure all identifying patient information is removed or scratched out.